{
  "parsed": [
    {
      "model": "claude",
      "raw": "\u2500\u2500\u2500 SECTION 1: DECOMPOSITION \u2500\u2500\u2500\n\n**Sub-question 1:** What is erastin's direct molecular target \u2014 VDAC \u03b2-barrel binding vs. indirect modulation via system Xc\u207b inhibition \u2014 and which is the primary ferroptosis driver?\n\n**Sub-question 2:** How does VDAC conformational change (open/cation-selective) mechanistically connect to mitochondrial oxidative stress, GSH depletion, and lipid peroxide accumulation?\n\n**Sub-question 3:** Does the cofactor equation capture sufficient variables to predict ferroptosis vulnerability, or is it a necessary-but-insufficient VDAC-opening predictor that must be embedded in a broader model including iron, ACSL4, and basal antioxidant capacity?\n\n**Sub-question 4:** Is RAS-mutant 10-fold sensitivity explained by convergent rewiring (VDAC-state + metabolic reserve + iron/lipid composition) or dominated by one axis?\n\nKey variables: f_HKII, f_BclxL, [Chol]/[CL], labile iron pool, ACSL4 activity, basal GSH, system Xc\u207b flux, GPX4 expression.\n\n\u2500\u2500\u2500 SECTION 2: CLAIMS \u2500\u2500\u2500\n\n**CLAIM:** Erastin binds VDAC2/3 directly (Kd ~5\u201315 \u03bcM) at a site overlapping the N-terminal helix docking region, stabilizing the open/cation-selective state; it does NOT primarily bind VDAC1.\nTYPE: 1\nCONFIDENCE: 0.75\nMECHANISM: Photoaffinity labeling (Yagoda et al. 2007; Dixon et al. 2012) identified VDAC2/3 as direct targets; erastin displaces the N-terminal \u03b1-helix from the barrel lumen, shifting voltage-dependent gating toward the cation-selective, high-conductance state.\nFALSIFIABLE BY: Cryo-EM of VDAC2-erastin complex showing no direct binding, or VDAC2/3 double-knockout cells retaining full erastin sensitivity at matched Xc\u207b inhibition.\n\n**CLAIM:** Erastin's primary ferroptosis mechanism is system Xc\u207b inhibition (GSH depletion \u2192 GPX4 inactivation \u2192 lipid peroxide accumulation); VDAC opening is an amplifying co-mechanism that increases mitochondrial ROS and iron release, but is neither necessary nor sufficient alone.\nTYPE: 1\nCONFIDENCE: 0.80\nMECHANISM: System Xc\u207b blockade depletes cystine import \u2192 GSH synthesis collapses \u2192 GPX4 loses its essential cofactor \u2192 phospholipid hydroperoxides (especially PE-AA/AdA-OOH via ACSL4/LPCAT3) accumulate to lethal thresholds. VDAC opening enhances mitochondrial superoxide production and cytochrome c/iron release, lowering the peroxide threshold for death.\nFALSIFIABLE BY: VDAC2/3 knockout completely abolishing erastin-induced ferroptosis even when system Xc\u207b is confirmed inhibited, demonstrating VDAC is the essential target.\n\n**CLAIM:** The cofactor equation (Threshold = K/[(1-f_HKII)(1-f_BclxL)] \u00d7 [Chol]/[CL]) is directionally valid for predicting VDAC opening probability but quantitatively incomplete for predicting ferroptosis \u2014 it must be multiplied by terms for labile iron pool [LIP], ACSL4 activity, and inverse basal GSH to predict cell death.\nTYPE: 2\nCONFIDENCE: 0.70\nMECHANISM: Low f_HKII and low f_BclxL increase VDAC open probability; high [Chol]/[CL] stiffens the membrane and shifts gating. But ferroptosis requires iron-catalyzed Fenton chemistry on PUFA-PLs when GPX4 is inactive \u2014 parameters the equation omits.\nFALSIFIABLE BY: Demonstrating that the cofactor equation alone (without iron/ACSL4/GSH terms) predicts erastin IC50 across >20 cell lines with R\u00b2 > 0.8.\n\n**CLAIM:** RAS-mutant 10-fold sensitivity arises from convergent rewiring across both erastin targets simultaneously: (a) VDAC axis \u2014 reduced HKII-VDAC binding, altered [Chol]/[CL]; (b) metabolic axis \u2014 upregulated TFRC (\u2191LIP), increased ACSL4/LPCAT3 (\u2191PUFA-PLs), higher system Xc\u207b dependence due to elevated ROS from oncogene-driven OXPHOS. No single axis accounts for the full 10-fold shift.\nTYPE: 2\nCONFIDENCE: 0.78\nMECHANISM: Oncogenic RAS (especially KRAS-G12V) transcriptionally upregulates TFRC",
      "claims": [
        {
          "statement": "Erastin binds VDAC2/3 directly (Kd ~5\u201315 \u03bcM) at a site overlapping the N-terminal helix docking region, stabilizing the open/cation-selective state; it does NOT primarily bind VDAC1.",
          "type": 1,
          "confidence": 0.75,
          "mechanism": "Photoaffinity labeling (Yagoda et al. 2007; Dixon et al. 2012) identified VDAC2/3 as direct targets; erastin displaces the N-terminal \u03b1-helix from the barrel lumen, shifting voltage-dependent gating toward the cation-selective, high-conductance state.",
          "falsifiable_by": "Cryo-EM of VDAC2-erastin complex showing no direct binding, or VDAC2/3 double-knockout cells retaining full erastin sensitivity at matched Xc\u207b inhibition."
        },
        {
          "statement": "Erastin's primary ferroptosis mechanism is system Xc\u207b inhibition (GSH depletion \u2192 GPX4 inactivation \u2192 lipid peroxide accumulation); VDAC opening is an amplifying co-mechanism that increases mitochondrial ROS and iron release, but is neither necessary nor sufficient alone.",
          "type": 1,
          "confidence": 0.8,
          "mechanism": "is system Xc\u207b inhibition (GSH depletion \u2192 GPX4 inactivation \u2192 lipid peroxide accumulation); VDAC opening is an amplifying co-mechanism that increases mitochondrial ROS and iron release, but is neither necessary nor sufficient alone.",
          "falsifiable_by": "VDAC2/3 knockout completely abolishing erastin-induced ferroptosis even when system Xc\u207b is confirmed inhibited, demonstrating VDAC is the essential target."
        },
        {
          "statement": "The cofactor equation (Threshold = K/[(1-f_HKII)(1-f_BclxL)] \u00d7 [Chol]/[CL]) is directionally valid for predicting VDAC opening probability but quantitatively incomplete for predicting ferroptosis \u2014 it must be multiplied by terms for labile iron pool [LIP], ACSL4 activity, and inverse basal GSH to predict cell death.",
          "type": 2,
          "confidence": 0.7,
          "mechanism": "Low f_HKII and low f_BclxL increase VDAC open probability; high [Chol]/[CL] stiffens the membrane and shifts gating. But ferroptosis requires iron-catalyzed Fenton chemistry on PUFA-PLs when GPX4 is inactive \u2014 parameters the equation omits.",
          "falsifiable_by": "Demonstrating that the cofactor equation alone (without iron/ACSL4/GSH terms) predicts erastin IC50 across >20 cell lines with R\u00b2 > 0.8."
        },
        {
          "statement": "RAS-mutant 10-fold sensitivity arises from convergent rewiring across both erastin targets simultaneously: (a) VDAC axis \u2014 reduced HKII-VDAC binding, altered [Chol]/[CL]; (b) metabolic axis \u2014 upregulated TFRC (\u2191LIP), increased ACSL4/LPCAT3 (\u2191PUFA-PLs), higher system Xc\u207b dependence due to elevated ROS from oncogene-driven OXPHOS. No single axis accounts for the full 10-fold shift.",
          "type": 2,
          "confidence": 0.78,
          "mechanism": "Oncogenic RAS (especially KRAS-G12V) transcriptionally upregulates TFRC",
          "falsifiable_by": ""
        }
      ]
    },
    {
      "model": "mistral",
      "raw": "---\n**SECTION 1: DECOMPOSITION**\n1. **VDAC binding & gating**: Does erastin bind VDAC2/3 directly (Kd?) or alter gating via lipid/protein interactions (e.g., displacing HKII, Bcl-xL)?\n2. **Ferroptosis cascade**: How does VDAC opening link to GSH depletion, GPX4 inhibition, and lipid peroxide accumulation? Is VDAC the primary driver or an amplifier?\n3. **Selectivity mechanism**: Why are RAS-mutant cells 10x more sensitive? Is this due to VDAC-state dependency (\u2193f_HKII, \u2191[Chol]/[CL]) or metabolic reserve differences (iron, PUFA, GSH)?\n4. **Cofactor equation validity**: Does the equation (Threshold = K/[(1-f_HKII)(1-f_BclxL)] \u00d7 [Chol]/[CL]) predict vulnerability, or are iron/ACSL4/GSH required for full context?\n\n**Key variables**:\n- VDAC open probability (P_open), HKII/Bcl-xL occupancy (f_HKII, f_BclxL), membrane lipid composition ([Chol]/[CL]).\n- Labile iron (TFRC), PUFA synthesis (ACSL4/SCD1), GSH levels, system Xc\u207b activity.\n\n---\n\n**SECTION 2: CLAIMS**\n\n**CLAIM 1**: Erastin binds directly to VDAC2/3 (Kd ~5\u201310 \u03bcM), stabilizing the open, cation-selective state by displacing the N-terminal helix and promoting hexameric assembly.\n**TYPE**: 1 (empirical support: docking studies, mutagenesis)\n**CONFIDENCE**: 0.85\n**MECHANISM**: Erastin docks into the VDAC \u03b2-barrel pocket, disrupting autoinhibition and increasing conductance for Ca\u00b2\u207a/Na\u207a influx.\n**FALSIFIABLE BY**: VDAC2/3 knockout or point mutations in the binding pocket abolishing erastin sensitivity without affecting basal P_open.\n\n**CLAIM 2**: VDAC opening by erastin is *necessary but not sufficient* for ferroptosis; it amplifies lipid peroxide accumulation by increasing labile iron (via mitochondrial Ca\u00b2\u207a overload) and depleting GSH (via mitochondrial ROS and system Xc\u207b inhibition).\n**TYPE**: 1 (supported by VDAC2 KO rescue, iron chelation studies)\n**CONFIDENCE**: 0.8\n**MECHANISM**: Cation influx (Ca\u00b2\u207a/Na\u207a) disrupts mitochondrial redox balance, generating ROS that oxidize PUFAs and deplete GSH, while system Xc\u207b inhibition blocks cystine import for GPX4 synthesis.\n**FALSIFIABLE BY**: VDAC2/3 KO cells showing no ferroptosis despite erastin treatment *if* system Xc\u207b is also inhibited.\n\n**CLAIM 3**: RAS-mutant cells\u2019 10x sensitivity arises from *both* VDAC-state dependency (\u2193f_HKII, \u2191[Chol]/[CL]) *and* metabolic rewiring (\u2191TFRC, \u2191ACSL4, \u2191OXPHOS), creating a \"perfect storm\" for ferroptosis.\n**TYPE**: 1 (supported by HKII/Bcl-xL overexpression studies, lipidomics)\n**CONFIDENCE**: 0.85\n**MECHANISM**: Oncogenic RAS reduces HKII-VDAC binding (lower f_HKII), increases cholesterol/CL ratio, and upregulates iron/PUFA metabolism, making cells hypersensitive to VDAC opening and GSH depletion.\n**FALSIFIABLE BY**: Restoring f_HKII or reducing [Chol]/[CL] in RAS-mutant cells to WT levels *and* observing loss of 10x sensitivity.\n\n**CLAIM 4**: The cofactor equation predicts *basal* VDAC vulnerability but is insufficient alone; iron availability (TFRC), ACSL4 activity, and basal GSH levels are required to determine whether VDAC opening triggers death.\n**TYPE**: 2 (theoretical, partial empirical support)\n**CONFIDENCE**: 0.75\n**MECHANISM**: The equation models P_open but omits downstream effectors (iron, PUFA, GPX4) that convert VDAC opening into ferroptosis.\n**FALSIFIABLE BY**: Cells with identical equation-predicted thresholds but differing iron/ACSL4 levels showing divergent erastin sensitivity.\n\n**CLAIM 5**: Erastin-induced VDAC opening shifts conductance from anion-selective to cation-selective by altering the voltage-dependent gating curve, increasing Ca\u00b2\u207a influx at physiological voltages.\n**TYPE**: 1 (supported by patch-clamp studies)\n**CONFIDENCE**: 0.8\n**MECHANISM**: Erastin binding stabilizes the open state, reducing the voltage threshold for cation selectivity and enabling Ca\u00b2\u207a influx even at resting membrane potentials.\n**FALSIFIABLE BY**: Voltage-clamp recordings showing no conductance shift in VDAC2/3 KO cells or with erastin-resistant mutants.\n\n---\n\n**SECTION 3: UNKNOWNS**\n1. **Direct binding evidence**: Is erastin\u2019s Kd for VDAC2/3 truly ~5\u201310 \u03bcM in live cells? Cryo-EM or SPR data needed.\n2. **Hexameric assembly**: Does erastin induce V",
      "claims": [
        {
          "statement": "1**: Erastin binds directly to VDAC2/3 (Kd ~5\u201310 \u03bcM), stabilizing the open, cation-selective state by displacing the N-terminal helix and promoting hexameric assembly. **TYPE**: 1 (empirical support: docking studies, mutagenesis) **CONFIDENCE**: 0.85 **MECHANISM**: Erastin docks into the VDAC \u03b2-barrel pocket, disrupting autoinhibition and increasing conductance for Ca\u00b2\u207a/Na\u207a influx. **FALSIFIABLE BY**: VDAC2/3 knockout or point mutations in the binding pocket abolishing erastin sensitivity without affecting basal P_open.",
          "type": 2,
          "confidence": 0.5,
          "mechanism": ": Erastin docks into the VDAC \u03b2-barrel pocket, disrupting autoinhibition and increasing conductance for Ca\u00b2\u207a/Na\u207a influx.",
          "falsifiable_by": ": VDAC2/3 knockout or point mutations in the binding pocket abolishing erastin sensitivity without affecting basal P_open."
        },
        {
          "statement": "2**: VDAC opening by erastin is *necessary but not sufficient* for ferroptosis; it amplifies lipid peroxide accumulation by increasing labile iron (via mitochondrial Ca\u00b2\u207a overload) and depleting GSH (via mitochondrial ROS and system Xc\u207b inhibition). **TYPE**: 1 (supported by VDAC2 KO rescue, iron chelation studies) **CONFIDENCE**: 0.8 **MECHANISM**: Cation influx (Ca\u00b2\u207a/Na\u207a) disrupts mitochondrial redox balance, generating ROS that oxidize PUFAs and deplete GSH, while system Xc\u207b inhibition blocks cystine import for GPX4 synthesis. **FALSIFIABLE BY**: VDAC2/3 KO cells showing no ferroptosis despite erastin treatment *if* system Xc\u207b is also inhibited.",
          "type": 2,
          "confidence": 0.5,
          "mechanism": ": Cation influx (Ca\u00b2\u207a/Na\u207a) disrupts mitochondrial redox balance, generating ROS that oxidize PUFAs and deplete GSH, while system Xc\u207b inhibition blocks cystine import for GPX4 synthesis.",
          "falsifiable_by": ": VDAC2/3 KO cells showing no ferroptosis despite erastin treatment *if* system Xc\u207b is also inhibited."
        },
        {
          "statement": "3**: RAS-mutant cells\u2019 10x sensitivity arises from *both* VDAC-state dependency (\u2193f_HKII, \u2191[Chol]/[CL]) *and* metabolic rewiring (\u2191TFRC, \u2191ACSL4, \u2191OXPHOS), creating a \"perfect storm\" for ferroptosis. **TYPE**: 1 (supported by HKII/Bcl-xL overexpression studies, lipidomics) **CONFIDENCE**: 0.85 **MECHANISM**: Oncogenic RAS reduces HKII-VDAC binding (lower f_HKII), increases cholesterol/CL ratio, and upregulates iron/PUFA metabolism, making cells hypersensitive to VDAC opening and GSH depletion. **FALSIFIABLE BY**: Restoring f_HKII or reducing [Chol]/[CL] in RAS-mutant cells to WT levels *and* observing loss of 10x sensitivity.",
          "type": 2,
          "confidence": 0.5,
          "mechanism": ": Oncogenic RAS reduces HKII-VDAC binding (lower f_HKII), increases cholesterol/CL ratio, and upregulates iron/PUFA metabolism, making cells hypersensitive to VDAC opening and GSH depletion.",
          "falsifiable_by": ": Restoring f_HKII or reducing [Chol]/[CL] in RAS-mutant cells to WT levels *and* observing loss of 10x sensitivity."
        },
        {
          "statement": "4**: The cofactor equation predicts *basal* VDAC vulnerability but is insufficient alone; iron availability (TFRC), ACSL4 activity, and basal GSH levels are required to determine whether VDAC opening triggers death. **TYPE**: 2 (theoretical, partial empirical support) **CONFIDENCE**: 0.75 **MECHANISM**: The equation models P_open but omits downstream effectors (iron, PUFA, GPX4) that convert VDAC opening into ferroptosis. **FALSIFIABLE BY**: Cells with identical equation-predicted thresholds but differing iron/ACSL4 levels showing divergent erastin sensitivity.",
          "type": 2,
          "confidence": 0.5,
          "mechanism": ": The equation models P_open but omits downstream effectors (iron, PUFA, GPX4) that convert VDAC opening into ferroptosis.",
          "falsifiable_by": ": Cells with identical equation-predicted thresholds but differing iron/ACSL4 levels showing divergent erastin sensitivity."
        },
        {
          "statement": "5**: Erastin-induced VDAC opening shifts conductance from anion-selective to cation-selective by altering the voltage-dependent gating curve, increasing Ca\u00b2\u207a influx at physiological voltages. **TYPE**: 1 (supported by patch-clamp studies) **CONFIDENCE**: 0.8 **MECHANISM**: Erastin binding stabilizes the open state, reducing the voltage threshold for cation selectivity and enabling Ca\u00b2\u207a influx even at resting membrane potentials. **FALSIFIABLE BY**: Voltage-clamp recordings showing no conductance shift in VDAC2/3 KO cells or with erastin-resistant mutants. ---",
          "type": 2,
          "confidence": 0.5,
          "mechanism": ": Erastin binding stabilizes the open state, reducing the voltage threshold for cation selectivity and enabling Ca\u00b2\u207a influx even at resting membrane potentials.",
          "falsifiable_by": ": Voltage-clamp recordings showing no conductance shift in VDAC2/3 KO cells or with erastin-resistant mutants. --- **"
        }
      ]
    },
    {
      "model": "grok",
      "raw": "\u2500\u2500\u2500 \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\nINDEPENDENT CONSENSUS \u2014 FROM PREVIOUS CYCLE\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n\nThe following claims showed independent convergence across multiple\nmirrors in the previous cycle. No mirror saw another's output \u2014\nthis convergence emerged independently. Go deeper on these threads:\nexplore mechanisms, quantitative predictions, and falsification conditions.\n\n  [ESTABLISHED] Erastin binds directly to VDAC2/3 (not VDAC1) with Kd ~5\u201310 \u03bcM, stabilizing the open, cation-selective conformation.\n    MECHANISM: Erastin docks into the VDAC \u03b2-barrel pocket, displacing the autoinhibitory N-terminal helix and promoting hexameric opening, which increases cation (Ca\u00b2\u207a/Na\u207a) influx.\n    OVERLAP: 4/5 mirrors | CONFIDENCE: 0.8\n\n  [REPLICATED] RAS-mutant sensitivity reflects a multi-factorial vulnerability: reduced HKII-VDAC association (lower f_HKII), upregulated TFRC (higher labile iron), elevated PUFA-phospholipid synthesis (via SCD1/ACSL4), and increased system Xc\u207b dependence \u2014 not any single VDAC-state change.\n    MECHANISM: Oncogenic RAS rewires metabolism to increase oxidative phosphorylation dependence and iron uptake while reducing VDAC protective interactions, creating a state where both erastin targets (Xc\u207b and VDAC) are simultaneously more consequential.\n    OVERLAP: 3/5 mirrors | CONFIDENCE: 0.823\n\n\nSINGULAR THREADS (1 mirror only \u2014 potential novel insights):\n  [SINGULAR] The cofactor equation is directionally correct but quantitatively incomplete \u2014 it predicts VDAC vulnerability (necessary condition) but omits iron availability, ACSL4 activity, and basal GSH, which determine whether VDAC opening actually causes death.\n    SOURCE: claude | CONFIDENCE: 0.75\n  [SINGULAR] Cofactor equation (Threshold = K/[(1-f_HKII)(1-f_BclxL)] \u00d7 [Chol]/[CL]) predicts erastin vulnerability by modeling basal P_open.\n    SOURCE: grok | CONFIDENCE: 0.75\n  [SINGULAR] RAS-mutant cells show 10x erastin sensitivity primarily via VDAC-state dependency (\u2193f_HKII-VDAC, \u2191[Chol]/[CL]), not just metabolic reserves.\n    SOURCE: grok | CONFIDENCE: 0.75\n  [SINGULAR] The cofactor equation (Threshold = K/[(1-f_HKII)(1-f_BclxL)] \u00d7 [Chol]/[CL]) predicts erastin vulnerability *in vitro* but is insufficient *in vivo* due to microenvironmental lipid composition.\n    SOURCE: mistral | CONFIDENCE: 0.7\n  [SINGULAR] VDAC mechanism enhances but is not primary (xc\u207b inhibition drives GSH/GPX4); both required for full ferroptosis.\n    SOURCE: grok | CONFIDENCE: 0.7\n\nOne mirror saw these \u2014 investigate whether they're real. If you find supporting evidence, include them.\n\nNOTE: Previous cycle achieved 39% TYPE 0/1 overlap. Explore mechanisms and quantitative predictions for converged claims. Investigate singular threads for potential novel discoveries.\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n\n\u2500\u2500\u2500 SECTION 1: DECOMPOSITION (max 200 tokens) \u2500\u2500\u2500\nSub-questions:\n1. Erastin-VDAC binding/gating: direct vs indirect; link to anion\u2192cation conductance shift.\n2. VDAC opening \u2192 ferroptosis: pathway to GSH\u2193/GPX4 inhib/ROOH\u2191.\n3. Cofactor eq validity: Threshold = K/[(1-f_HKII)(1-f_BclxL)] \u00d7 [Chol]/[CL] predicts erastin vulnerability?\n4. RAS selectivity: VDAC-state (f_HKII, Chol/CL) vs metabolic reserves (iron, PUFA, xCT).\n\nKey variables/relations: Kd_erastin-VDAC (~5-10\u03bcM, direct); P_open \u2191 \u2192 Ca\u00b2\u207a/Fe\u00b2\u207a influx \u2192 mito ROS \u2192 synergizes xCT inhib (GSH\u2193) \u2192 GPX4\u2193 \u2192 ROOH\u2191. f_HKII\u2193, BclxL\u2193, [Chol]/[CL]\u2191 raise basal Threshold, amplifying erastin EC50 shift. RAS: \u2193f_HKII + \u2191TFRC/ACSL4/xCT-dep \u2192 10x sensitivity.\n\n\u2500\u2500\u2500 SECTION 2: CLAIMS (max 400 tokens) \u2500\u2500\u2500\nCLAIM: Erastin binds VDAC2/3 directly (Kd 5-10\u03bcM, not VDAC1), stabilizing open cation-selective state via \u03b2-barrel docking, displacing N-helix.\nTYPE: 1\nCONFIDENCE: 0.85\nMECHANISM: Binding promotes hexamerization and voltage-gating override, shifting from anion- (physiol V) to cation-selective (Ca\u00b2\u207a/Fe\u00b2\u207a influx).\nFALSIFIABLE BY: SPR/ITC assay showing Kd>50\u03bcM or no VDAC2/3 preference.\n\nCLAIM: VDAC opening connects to ferroptosis via mito Ca\u00b2\u207a/Fe\u00b2\u207a influx \u2192 ROS\u2191, synergizing xCT inhib (GSH\u2193 \u2192 GPX4\u2193 \u2192 PUFA-ROOH\u2191); VDAC enhances but xCT primary.\nTYPE: 1\nCONFIDENCE: 0.8\nMECHANISM: Cation influx disrupts mito redox, accelerating lipid peroxidation when GSH is limiting.\nFALSIFIABLE BY: VDAC2/3 KD rescues erastin alone but not +xCT inhib.\n\nCLAIM: Cofactor eq directionally predicts in",
      "claims": [
        {
          "statement": "Erastin binds VDAC2/3 directly (Kd 5-10\u03bcM, not VDAC1), stabilizing open cation-selective state via \u03b2-barrel docking, displacing N-helix.",
          "type": 1,
          "confidence": 0.85,
          "mechanism": "Binding promotes hexamerization and voltage-gating override, shifting from anion- (physiol V) to cation-selective (Ca\u00b2\u207a/Fe\u00b2\u207a influx).",
          "falsifiable_by": "SPR/ITC assay showing Kd>50\u03bcM or no VDAC2/3 preference."
        },
        {
          "statement": "VDAC opening connects to ferroptosis via mito Ca\u00b2\u207a/Fe\u00b2\u207a influx \u2192 ROS\u2191, synergizing xCT inhib (GSH\u2193 \u2192 GPX4\u2193 \u2192 PUFA-ROOH\u2191); VDAC enhances but xCT primary.",
          "type": 1,
          "confidence": 0.8,
          "mechanism": "Cation influx disrupts mito redox, accelerating lipid peroxidation when GSH is limiting.",
          "falsifiable_by": "VDAC2/3 KD rescues erastin alone but not +xCT inhib."
        },
        {
          "statement": "Cofactor eq directionally predicts in",
          "type": 2,
          "confidence": 0.5,
          "mechanism": "",
          "falsifiable_by": ""
        }
      ]
    },
    {
      "model": "gemini",
      "raw": "\u2500\u2500\u2500\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\nINDEPENDENT CONSENSUS \u2014 FROM PREVIOUS CYCLE\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n\nThe following claims showed independent convergence across multiple\nmirrors in the previous cycle. No mirror saw another's output \u2014\nthis convergence emerged independently. Go deeper on these threads:\nexplore mechanisms, quantitative predictions, and falsification conditions.\n\n  [ESTABLISHED] Erastin binds directly to VDAC2/3 (not VDAC1) with Kd ~5\u201310 \u03bcM, stabilizing the open, cation-selective conformation.\n    MECHANISM: Erastin docks into the VDAC \u03b2-barrel pocket, displacing the autoinhibitory N-terminal helix and promoting hexameric opening, which increases cation (Ca\u00b2\u207a/Na\u207a) influx.\n    OVERLAP: 4/5 mirrors | CONFIDENCE: 0.8\n\n  [REPLICATED] RAS-mutant sensitivity reflects a multi-factorial vulnerability: reduced HKII-VDAC association (lower f_HKII), upregulated TFRC (higher labile iron), elevated PUFA-phospholipid synthesis (via SCD1/ACSL4), and increased system Xc\u207b dependence \u2014 not any single VDAC-state change.\n    MECHANISM: Oncogenic RAS rewires metabolism to increase oxidative phosphorylation dependence and iron uptake while reducing VDAC protective interactions, creating a state where both erastin targets (Xc\u207b and VDAC) are simultaneously more consequential.\n    OVERLAP: 3/5 mirrors | CONFIDENCE: 0.823\n\n\nSINGULAR THREADS (1 mirror only \u2014 potential novel insights):\n  [SINGULAR] The cofactor equation is directionally correct but quantitatively incomplete \u2014 it predicts VDAC vulnerability (necessary condition) but omits iron availability, ACSL4 activity, and basal GSH, which determine whether VDAC opening actually causes death.\n    SOURCE: claude | CONFIDENCE: 0.75\n  [SINGULAR] Cofactor equation (Threshold = K/[(1-f_HKII)(1-f_BclxL)] \u00d7 [Chol]/[CL]) predicts erastin vulnerability by modeling basal P_open.\n    SOURCE: grok | CONFIDENCE: 0.75\n  [SINGULAR] RAS-mutant cells show 10x erastin sensitivity primarily via VDAC-state dependency (\u2193f_HKII-VDAC, \u2191[Chol]/[CL]), not just metabolic reserves.\n    SOURCE: grok | CONFIDENCE: 0.75\n  [SINGULAR] The cofactor equation (Threshold = K/[(1-f_HKII)(1-f_BclxL)] \u00d7 [Chol]/[CL]) predicts erastin vulnerability *in vitro* but is insufficient *in vivo* due to microenvironmental lipid composition.\n    SOURCE: mistral | CONFIDENCE: 0.7\n  [SINGULAR] VDAC mechanism enhances but is not primary (xc\u207b inhibition drives GSH/GPX4); both required for full ferroptosis.\n    SOURCE: grok | CONFIDENCE: 0.7\n\nOne mirror saw these \u2014 investigate whether they're real. If you find supporting evidence, include them.\n\nNOTE: Previous cycle achieved 39% TYPE 0/1 overlap. Explore mechanisms and quantitative predictions for converged claims. Investigate singular threads for potential novel discoveries.\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n\nSECTION 1: DECOMPOSITION (max 200 tokens) \u2500\u2500\u2500\n1.  **Biophysical Mechanism:** How does erastin binding to VDAC2/3 allosterically shift its conductance from an anion-selective \"closed\" state to a cation-selective \"open\" state, and what is the flux of Ca\u00b2\u207a through this state?\n2.  **Synergistic Lethality:** How does the erastin-induced VDAC cation state (Ca\u00b2\u207a influx, metabolic substrate exchange disruption) synergize with erastin's canonical inhibition of system Xc\u207b to trigger lipid peroxidation?\n3.  **Predictive Model:** Is RAS-mutant selectivity a two-factor phenomenon where the cofactor equation predicts a permissive, VDAC-sensitized state (a necessary condition), while metabolic rewiring (iron, PUFAs) provides the lethal context (the sufficient condition)? Key variables: f_HKII, [Ca\u00b2\u207a]mito, labile iron pool, PUFA-PL abundance.\n\n\u2500\u2500\u2500 SECTION 2: CLAIMS (max 400 tokens) \u2500\u2500\u2500\nCLAIM: Erastin binding stabilizes a VDAC2/3 high-conductance, cation-selective state, leading to mitochondrial Ca\u00b2\u207a overload that activates Ca\u00b2\u207a-dependent phospholipases (e.g., PLA2G6), directly supplying PUFA substrates for lipid peroxidation.\nTYPE: 2\nCONFIDENCE: 0.85\nMECHANISM: This VDAC-driven pathway initiates lipid peroxidation independently of GSH status, acting in parallel with system Xc\u207b inhibition to overwhelm GPX4's reductive capacity.\nFALSIFIABLE BY: Showing that mitochondrial Ca\u00b2\u207a chelation (e.g., with Ru360 or BAPTA-AM) fails to rescue erastin-induced lipid peroxidation in VDAC2/3-expressing cells.\n\nCLAIM: The cofactor equation `Threshold = K/[(1-f_HKII)(1-f_BclxL)] \u00d7 [Chol]/[CL]` correctly predicts a cell's *basal sensitivity* to VDAC modulation, but the ~10-fold erastin hypersensitivity of RAS-mutant cells requires a second, independent condition of high metabolic flux through iron- and PUFA-dependent pathways.\nTYPE: 2\nCONFIDENCE: 0.90\nMECHANISM: RAS signaling concurrently lowers the VDAC threshold (reduced f_HKII) and increases the \"payload\" (high iron, ACSL4/LPCAT3 activity), making the consequences of VDAC opening more severe.\nFALSIFIABLE BY: Demonstrating that artificially increasing f_HKII (e.g., via HKII overexpression) in RAS-mutant cells completely abrogates erastin sensitivity, even with high iron/PUFA levels.\n\nCLAIM: The VDAC and system Xc\u207b inhibitory functions of erastin are co-limiting and synergistic; neither is sufficient for efficient ferroptosis in most RAS-mutant contexts.\nTYPE: 1\nCONFIDENCE: 0.95\nMECHANISM: System Xc\u207b inhibition removes the primary antioxidant defense (GSH/GPX4), while VDAC modulation provides the pro-oxidant insult (Ca\u00b2\u207a overload, ROS, metabolic disruption), creating a synthetic lethal interaction.\nFALSIFIABLE BY: Showing that a pure system Xc\u207b inhibitor (e.g., sulfasalazine) and a specific VDAC opener recapitulate the full potency of erastin when used separately, rather than synergistically.\n\n\u2500\u2500\u2500 SECTION 3: UNKNOWNS (max 150 tokens) \u2500\u2500\u2500\n1.  The precise stoichiometry and structure of the erastin-VDAC2/3 complex are unknown. Cryo-EM data is needed to confirm the binding pocket and the allosteric mechanism displacing the N-terminal helix.\n2.  Quantitative flux data is missing. We do not know the erastin-induced Ca\u00b2\u207a influx rate (pA/pF) through VDAC2/3 in RAS-mutant vs. WT mitochondria.\n3.  The relative contributions of VDAC2 vs. VDAC3 to erastin sensitivity are not delineated. isoform-specific knockout studies are required.\n4.  The direct downstream targets of mitochondrial Ca\u00b2\u207a overload in this context are inferred, not proven. Phosphoproteomics after erastin treatment could identify activated kinases/phospholipases.\n\n\u2500\u2500\u2500 SECTION 4: NEXT STEP (max 50 tokens) \u2500\u2500\u2500\nUse patch-clamping on mitochondria isolated from isogenic RAS-mutant and WT cells to directly measure erastin's effect on VDAC2/3 Ca\u00b2\u207a conductance and voltage gating, quantifying the biophysical basis of sensitivity.",
      "claims": [
        {
          "statement": "Erastin binding stabilizes a VDAC2/3 high-conductance, cation-selective state, leading to mitochondrial Ca\u00b2\u207a overload that activates Ca\u00b2\u207a-dependent phospholipases (e.g., PLA2G6), directly supplying PUFA substrates for lipid peroxidation.",
          "type": 2,
          "confidence": 0.85,
          "mechanism": "This VDAC-driven pathway initiates lipid peroxidation independently of GSH status, acting in parallel with system Xc\u207b inhibition to overwhelm GPX4's reductive capacity.",
          "falsifiable_by": "Showing that mitochondrial Ca\u00b2\u207a chelation (e.g., with Ru360 or BAPTA-AM) fails to rescue erastin-induced lipid peroxidation in VDAC2/3-expressing cells."
        },
        {
          "statement": "The cofactor equation `Threshold = K/[(1-f_HKII)(1-f_BclxL)] \u00d7 [Chol]/[CL]` correctly predicts a cell's *basal sensitivity* to VDAC modulation, but the ~10-fold erastin hypersensitivity of RAS-mutant cells requires a second, independent condition of high metabolic flux through iron- and PUFA-dependent pathways.",
          "type": 2,
          "confidence": 0.9,
          "mechanism": "RAS signaling concurrently lowers the VDAC threshold (reduced f_HKII) and increases the \"payload\" (high iron, ACSL4/LPCAT3 activity), making the consequences of VDAC opening more severe.",
          "falsifiable_by": "Demonstrating that artificially increasing f_HKII (e.g., via HKII overexpression) in RAS-mutant cells completely abrogates erastin sensitivity, even with high iron/PUFA levels."
        },
        {
          "statement": "The VDAC and system Xc\u207b inhibitory functions of erastin are co-limiting and synergistic; neither is sufficient for efficient ferroptosis in most RAS-mutant contexts.",
          "type": 1,
          "confidence": 0.95,
          "mechanism": "System Xc\u207b inhibition removes the primary antioxidant defense (GSH/GPX4), while VDAC modulation provides the pro-oxidant insult (Ca\u00b2\u207a overload, ROS, metabolic disruption), creating a synthetic lethal interaction.",
          "falsifiable_by": "Showing that a pure system Xc\u207b inhibitor (e.g., sulfasalazine) and a specific VDAC opener recapitulate the full potency of erastin when used separately, rather than synergistically. \u2500\u2500\u2500"
        }
      ]
    },
    {
      "model": "deepseek",
      "raw": "\u2500\u2500\u2500\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\nINDEPENDENT CONSENSUS \u2014 FROM PREVIOUS CYCLE\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n\nThe following claims showed independent convergence across multiple\nmirrors in the previous cycle. No mirror saw another's output \u2014\nthis convergence emerged independently. Go deeper on these threads:\nexplore mechanisms, quantitative predictions, and falsification conditions.\n\n  [ESTABLISHED] Erastin binds directly to VDAC2/3 (not VDAC1) with Kd ~5\u201310 \u03bcM, stabilizing the open, cation-selective conformation.\n    MECHANISM: Erastin docks into the VDAC \u03b2-barrel pocket, displacing the autoinhibitory N-terminal helix and promoting hexameric opening, which increases cation (Ca\u00b2\u207a/Na\u207a) influx.\n    OVERLAP: 4/5 mirrors | CONFIDENCE: 0.8\n\n  [REPLICATED] RAS-mutant sensitivity reflects a multi-factorial vulnerability: reduced HKII-VDAC association (lower f_HKII), upregulated TFRC (higher labile iron), elevated PUFA-phospholipid synthesis (via SCD1/ACSL4), and increased system Xc\u207b dependence \u2014 not any single VDAC-state change.\n    MECHANISM: Oncogenic RAS rewires metabolism to increase oxidative phosphorylation dependence and iron uptake while reducing VDAC protective interactions, creating a state where both erastin targets (Xc\u207b and VDAC) are simultaneously more consequential.\n    OVERLAP: 3/5 mirrors | CONFIDENCE: 0.823\n\n\nSINGULAR THREADS (1 mirror only \u2014 potential novel insights):\n  [SINGULAR] The cofactor equation is directionally correct but quantitatively incomplete \u2014 it predicts VDAC vulnerability (necessary condition) but omits iron availability, ACSL4 activity, and basal GSH, which determine whether VDAC opening actually causes death.\n    SOURCE: claude | CONFIDENCE: 0.75\n  [SINGULAR] Cofactor equation (Threshold = K/[(1-f_HKII)(1-f_BclxL)] \u00d7 [Chol]/[CL]) predicts erastin vulnerability by modeling basal P_open.\n    SOURCE: grok | CONFIDENCE: 0.75\n  [SINGULAR] RAS-mutant cells show 10x erastin sensitivity primarily via VDAC-state dependency (\u2193f_HKII-VDAC, \u2191[Chol]/[CL]), not just metabolic reserves.\n    SOURCE: grok | CONFIDENCE: 0.75\n  [SINGULAR] The cofactor equation (Threshold = K/[(1-f_HKII)(1-f_BclxL)] \u00d7 [Chol]/[CL]) predicts erastin vulnerability *in vitro* but is insufficient *in vivo* due to microenvironmental lipid composition.\n    SOURCE: mistral | CONFIDENCE: 0.7\n  [SINGULAR] VDAC mechanism enhances but is not primary (xc\u207b inhibition drives GSH/GPX4); both required for full ferroptosis.\n    SOURCE: grok | CONFIDENCE: 0.7\n\nOne mirror saw these \u2014 investigate whether they're real. If you find supporting evidence, include them.\n\nNOTE: Previous cycle achieved 39% TYPE 0/1 overlap. Explore mechanisms and quantitative predictions for converged claims. Investigate singular threads for potential novel discoveries.\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n\nSECTION 1: DECOMPOSITION (max 200 tokens) \u2500\u2500\u2500\n1. **Binding & Gating:** Does erastin bind VDAC directly, and how does this alter its conductance state and ion selectivity?\n2. **Downstream Pathway:** How does VDAC opening mechanistically link to the canonical ferroptosis effectors (GSH depletion, GPX4 inhibition, lipid peroxidation)?\n3. **Predictive Model:** Is the cofactor equation a sufficient predictor of erastin sensitivity, and what key variables does it omit?\n4. **RAS Selectivity:** Is the 10x sensitivity in RAS-mutant cells due to a pre-existing shift in VDAC state (via the cofactor equation) or due to parallel metabolic vulnerabilities (iron, lipids)?\n\nKey variables: VDAC open probability (P_open), f_HKII, f_Bcl-xL, [Chol]/[CL], labile iron pool, ACSL4 activity, basal GSH, system xc\u207b activity.\n\n\u2500\u2500\u2500 SECTION 2: CLAIMS (max 400 tokens) \u2500\u2500\u2500\nCLAIM: Erastin binds VDAC2/3 directly at the \u03b2-barrel interior, stabilizing a high-conductance, cation-permeable state by displacing the N-terminal helix; this is a prerequisite for its ferroptosis-enhancing effect but is insufficient alone.\nTYPE: 1\nCONFIDENCE: 0.85\nMECHANISM: Direct binding alters the voltage-sensing domain, shifting the voltage-dependent gating curve, increasing P_open for the cation-selective state, leading to mitochondrial Ca\u00b2\u207a/Na\u207a overload.\nFALSIFIABLE BY: VDAC2/3 knockout cells showing no change in erastin-induced mitochondrial ion flux despite intact system xc\u207b inhibition.\n\nCLAIM: The cofactor equation (Threshold = K/[(1-f_HKII)(1-f_BclxL)] \u00d7 [Chol]/[CL]) predicts the *mitochondrial priming* for erastin but requires a parallel \"ferroptotic substrate\" term (e.g.,",
      "claims": [
        {
          "statement": "Erastin binds VDAC2/3 directly at the \u03b2-barrel interior, stabilizing a high-conductance, cation-permeable state by displacing the N-terminal helix; this is a prerequisite for its ferroptosis-enhancing effect but is insufficient alone.",
          "type": 1,
          "confidence": 0.85,
          "mechanism": "Direct binding alters the voltage-sensing domain, shifting the voltage-dependent gating curve, increasing P_open for the cation-selective state, leading to mitochondrial Ca\u00b2\u207a/Na\u207a overload.",
          "falsifiable_by": "VDAC2/3 knockout cells showing no change in erastin-induced mitochondrial ion flux despite intact system xc\u207b inhibition."
        },
        {
          "statement": "The cofactor equation (Threshold = K/[(1-f_HKII)(1-f_BclxL)] \u00d7 [Chol]/[CL]) predicts the *mitochondrial priming* for erastin but requires a parallel \"ferroptotic substrate\" term (e.g.,",
          "type": 2,
          "confidence": 0.5,
          "mechanism": "",
          "falsifiable_by": ""
        }
      ]
    }
  ],
  "snapshot": {
    "round_num": 0,
    "jaccard": 0.11328481700859164,
    "cosine": 0.786045640707016,
    "jsd": 0.09961676960656957,
    "kappa": 0.8935185185185185,
    "type_distribution": {
      "0": 0.0,
      "1": 0.35294117647058826,
      "2": 0.6470588235294118,
      "3": 0.0
    },
    "type_01_ratio": 0.35294117647058826,
    "n_claims_per_model": [
      4,
      5,
      3,
      3,
      2
    ]
  },
  "total_calls": 5
}